 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Aprea Therapeutics announces preclinical data on its ATRN-1051 candidate

Demonstrating potential safety and efficacy of WEE1 inhibitor, ATRN-1051, in the treatment of ovarian cancer Company anticipates submitting an IND by the end of 2023 Data to be presented at an...

Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors

DOYLESTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) ( Aprea or the Company ), a clinical stage biopharmaceutical company focused on precision oncology...

Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

DOYLESTOWN, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (Aprea, or the Company), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it has appointed Dr. Jean-Pierre Bizzari to its Board of Directors...

Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman

Aprea Therapeutics, Inc. (NASDAQ:APRE  Free Report)  Research analysts at HC Wainwright increased their Q3 2023 earnings per share (EPS) estimates for Aprea Therapeutics in a research report issued on Thursday, August 10th. HC Wainwright analyst J. Pantginis now expects that the ...

HC Wainwright Equities Analysts Increase Earnings Estimates for Aprea Therapeutics, Inc. (NASDAQ:APRE)

Aprea Therapeutics, Inc. (NASDAQ:APRE Free Report) Investment analysts at HC Wainwright raised their Q3 2023 earnings estimates for shares of Aprea Therapeutics in a research report issued on Thursday, August 10th. HC Wainwright analyst J. Pantginis now anticipates that the company will post ...

HC Wainwright Analysts Raise Earnings Estimates for Aprea Therapeutics, Inc. (NASDAQ:APRE)

Aprea Therapeutics (APRE) Investor Presentation - Slideshow

HC Wainwright reiterated their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE Free Report) in a report published on Thursday morning, Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock. Aprea Therapeutics Stock Performance Shares of APRE opened at $3.99 on ...

Aprea Therapeutics (NASDAQ:APRE) Rating Reiterated by HC Wainwright

DOYLESTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc.(Nasdaq: APRE) (Aprea, or the Company), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and six months ended June 30, 2023 ...

Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations

Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board PR Newswire LEIDEN, The...

Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.

Watchers	9,163
52-Wk Low	$0.474
52-Wk High	$16.75

Market Cap	$15.51M
Volume (M)	7,195.00
52-Wk High	$16.75
52-Wk Low	$0.474

APRE Aprea Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals